Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: An interim analysis of the atezobladderpreserve phase II trial (SOGUG-2017-A-IEC(VEJ)-4)

被引：0

作者：

Calvo, Ovidio Fernandez

Bonfill, Teresa

Madueno, Francisca Martinez

Romero-Laorden, Nuria

Sequero-Lopez, Silvia

Domenech-Santasusana, Montserrat

Sevillano, Elena

Sanchez, Jose Garcia

Roman, Pilar Canoa

Alvarez-Fernandez, Carlos

Vazquez-Estevez, Sergio

机构：

[1] Complejo Hosp Univ Ourense, Med Oncol Dept, Orense, Spain

[2] Hosp Univ Parc Tauli, Sabadell, Spain

[3] HU St Joan Reus, Reus, Spain

[4] Hosp Univ Princesa, Madrid, Spain

[5] Hosp Univ San Cecilio, Granada, Spain

[6] Fundacio Althaia, Dept Med Oncol, Barcelona, Spain

[7] Fundacio Althaia, Dept Med Oncol, Manresa, Spain

[8] HM Sanchinarro Ctr Integral Oncol Clara CIOCC, Madrid, Spain

[9] Hosp Arnau Vilanova Valencia, Valencia, Spain

[10] Hosp Univ Lucus Augusti, Lugo, Spain

[11] Hosp Univ Cent Asturias, Med Oncol Dept, Oviedo, Spain

[12] Hosp Univ Lucus Augusti HULA, EOXI Lugo, Lugo, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4592

引用

页数：1

共 50 条

[31] Phase II trial of neoadjuvant nivolumab with cisplatin and gemcitabine in muscle-invasive bladder cancer patients undergoing radical cystectomy.
Gupta, Shilpa
Agarwal, Neeraj
Konety, Badrinath R.
Weight, Christopher J.
Thyagarajan, Bharat
Murugan, Paari J.
Koopmeiners, Joseph S.
Sonpavde, Guru
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[32] The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial
Daneshmand, Siamak
Brummelhuis, Iris S. G.
Pohar, Kamal S.
Steinberg, Gary D.
Aron, Manju
Cutie, Christopher J.
Keegan, Kirk A.
Maffeo, John C.
Reynolds, Donald L.
Raybold, Bradley
Chau, Albert
Witjes, J. Alfred
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (07) : 344.e1 - 344.e9
[33] Efficacy and safety of disitamab vedotin combined with gemcitabine as neoadjuvant therapy for muscle-invasive bladder cancer: A multi-center, single-arm, phase II trial
Yang, C.
Huang, H.
Zeng, X.
Dai, H.
Zhou, G.
Wang, S.
Hu, Z.
ANNALS OF ONCOLOGY, 2024, 35 : S1148 - S1148
[34] Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial
Szabados, Bernadett
Rodriguez-Vida, Alejo
Duran, Ignacio
Crabb, Simon J.
Van der Heijden, Michiel S.
Pous, Albert Font
Gravis, Gwenaelle
Herranz, Urbano Anido
Protheroe, Andrew
Ravaud, Alain
Maillet, Denis
Mendez-Vidal, Maria J.
Suarez, Cristina
Linch, Mark
Prendergast, Aaron
Tyson, Charlotte
Mousa, Kelly
Castellano, Daniel
Powles, Thomas
EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (03): : 456 - 463
[35] A PHASE I/II TRIAL OF TRANSURETHRAL SURGERY FOLLOWED BY A COMBINATION OF ATEZOLIZUMAB AN ANTI-PDL-1 (MPDL3280A) WITH TRIMODAL THERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER
Marcq, Gautier
Souhami, Luis
Cury, Fabio
Aprikian, Armen
Tanguay, Simon
Vanhuyse, Marie
Rajan, Raghu
Brimo, Fadi
Mansure, Jose Joao
Kassouf, Wassim
JOURNAL OF UROLOGY, 2020, 203 : E938 - E938
[36] Efficacy outcomes and biomarker analysis from phase II trial of escalating doses of neoadjuvant atezolizumab in patients with muscle-invasive urothelial carcinoma ineligible for cisplatin-based chemotherapy
Koshkin, Vadim S.
Jindal, Tanya
He, Jun Yan
Zhang, Li
Galang, Celine N.
Natesan, Divya
Kumar, Vipul
Zhu, Xiaolin
Chou, Jonathan
Aggarwal, Rahul Raj
Small, Eric J.
Meng, Maxwell
Porten, Sima P.
Oh, David Yoonsuk
Fong, Lawrence
Friedlander, Terence W.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 602 - 602
[37] Transurethral Resection of Bladder Tumor (TURBT) Followed By Partial Hypo-Fractionated Radiotherapy Concurrent with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer (MIBC): Acute Toxicities of a Prospective Phase II Study
Qin, S. B.
Gao, X. S.
Zhang, C. J.
Li, H. Z.
Yao, L.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E252 - E253
[38] Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial.
Funt, Samuel Aaron
Lattanzi, Michael
Whiting, Karissa
Al-Ahmadie, Hikmat A.
Quinlan, Colleen
Teo, Min Yuen
Kamradt, Jeffrey
Khalil, Maged F.
Ostrovnaya, Irina
Mccoy, Asia S.
Hettich, Grace
Jihad, Marwah
Folefac, Edmund
Huang, William C.
Bajorin, Dean F.
Iyer, Gopa
Bochner, Bernard H.
Balar, Arjun Vasant
Mortazavi, Amir
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[39] Efficacy and Safety of Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Interim Analysis from a Multicenter, Open-label, Prospective Phase 2 Trial
Kimura, Tomokazu
Ishikawa, Hitoshi
Nagumo, Yoshiyuki
Sekino, Yuta
Kageyama, Yukio
Ushijima, Hiroki
Kawai, Taketo
Yamashita, Hideomi
Azuma, Haruhito
Nihei, Keiji
Takemura, Masae
Hashimoto, Koichi
Maruo, Kazushi
Tsuzuki, Toyonori
Nishiyama, Hiroyuki
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (03): : 644 - 651
[40] Efficacy and safety of low-dose radiotherapy (LDRT) concurrent atezolizumab plus chemotherapy as first-line therapy for ES-SCLC : Interim analysis of Phase II MATCH trial.
Zhou, Lin
Sun, Jianguo
Xie, Conghua
Gong, Youling
Huang, Meijuan
Yuan, Zhiyong
Wu, Lin
Wang, Hui
Bi, Nan
Xu Yaping
Zhu, Jiang
Zhang, Yan
Fan, Min
Zou, Bingwen
Yu, Min
Na, Feifei
Xiu, Weigang
Zhang, Xuanwei
Xue, Jianxin
Lu, You
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →